171 related articles for article (PubMed ID: 37377611)
1. Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations.
Aoki K; Nishito Y; Motoi N; Arai Y; Hiraoka N; Shibata T; Sonobe Y; Kayukawa Y; Hashimoto E; Takahashi M; Fujii E; Nishizawa T; Fukuda H; Ohashi K; Arai K; Mizoguchi Y; Yoshida Y; Watanabe SI; Yamashita M; Kitano S; Sakamoto H; Nagata Y; Mitsumori R; Ozaki K; Niida S; Kanai Y; Hirayama A; Soga T; Maruyama T; Tsukada K; Yabuki N; Shimada M; Kitazawa T; Natori O; Sawada N; Kato A; Yoshida T; Yasuda K; Mizuno H; Tsunoda H; Ochiai A
Cancer Res Commun; 2023 Jun; 3(6):1026-1040. PubMed ID: 37377611
[TBL] [Abstract][Full Text] [Related]
2. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
3. Identification of the cell cycle characteristics of non-small cell lung cancer and its relationship with tumor immune microenvironment, cell death pathways, and metabolic reprogramming.
Cao S; Xiao S; Zhang J; Li S
Front Endocrinol (Lausanne); 2023; 14():1147366. PubMed ID: 37091844
[TBL] [Abstract][Full Text] [Related]
4. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes.
Shah P; Forget MA; Frank ML; Jiang P; Sakellariou-Thompson D; Federico L; Khairullah R; Neutzler CA; Wistuba I; Chow CB; Long Y; Fujimoto J; Lin SY; Maitra A; Negrao MV; Mitchell KG; Weissferdt A; Vaporciyan AA; Cascone T; Roth JA; Zhang J; Sepesi B; Gibbons DL; Heymach JV; Haymaker CL; McGrail DJ; Reuben A; Bernatchez C
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110355
[TBL] [Abstract][Full Text] [Related]
5. Multiplatform-based molecular subtypes of non-small-cell lung cancer.
Chen F; Zhang Y; Parra E; Rodriguez J; Behrens C; Akbani R; Lu Y; Kurie JM; Gibbons DL; Mills GB; Wistuba II; Creighton CJ
Oncogene; 2017 Mar; 36(10):1384-1393. PubMed ID: 27775076
[TBL] [Abstract][Full Text] [Related]
6. Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments.
Fukuda H; Arai K; Mizuno H; Nishito Y; Motoi N; Arai Y; Hiraoka N; Shibata T; Sonobe Y; Kayukawa Y; Hashimoto E; Takahashi M; Fujii E; Maruyama T; Kuwabara K; Nishizawa T; Mizoguchi Y; Yoshida Y; Watanabe SI; Yamashita M; Kitano S; Sakamoto H; Nagata Y; Mitsumori R; Ozaki K; Niida S; Kanai Y; Hirayama A; Soga T; Tsukada K; Yabuki N; Shimada M; Kitazawa T; Natori O; Sawada N; Kato A; Yoshida T; Yasuda K; Ochiai A; Tsunoda H; Aoki K
Cancer Sci; 2024 Mar; ():. PubMed ID: 38527308
[TBL] [Abstract][Full Text] [Related]
7. Transcriptome-based molecular subtyping of non-small cell lung cancer may predict response to immune checkpoint inhibitors.
Jang HJ; Lee HS; Ramos D; Park IK; Kang CH; Burt BM; Kim YT
J Thorac Cardiovasc Surg; 2020 Apr; 159(4):1598-1610.e3. PubMed ID: 31879171
[TBL] [Abstract][Full Text] [Related]
8. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
[TBL] [Abstract][Full Text] [Related]
9. Immune profiling reveals the diverse nature of the immune response in NSCLC and reveals signaling pathways that may influence the anti-tumor immune response.
Hamm CA; Pry K; Lu J; Bacus S
Exp Mol Pathol; 2019 Aug; 109():1-15. PubMed ID: 30953647
[TBL] [Abstract][Full Text] [Related]
10. An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer.
Karasaki T; Nagayama K; Kuwano H; Nitadori JI; Sato M; Anraku M; Hosoi A; Matsushita H; Morishita Y; Kashiwabara K; Takazawa M; Ohara O; Kakimi K; Nakajima J
J Thorac Oncol; 2017 May; 12(5):791-803. PubMed ID: 28088513
[TBL] [Abstract][Full Text] [Related]
11. The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing.
Wang C; Yu Q; Song T; Wang Z; Song L; Yang Y; Shao J; Li J; Ni Y; Chao N; Zhang L; Li W
Signal Transduct Target Ther; 2022 Aug; 7(1):289. PubMed ID: 36008393
[TBL] [Abstract][Full Text] [Related]
12. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
[TBL] [Abstract][Full Text] [Related]
13. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
Yoshimura K; Inoue Y; Tsuchiya K; Karayama M; Yamada H; Iwashita Y; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Lung Cancer; 2020 Mar; 141():21-31. PubMed ID: 31931443
[TBL] [Abstract][Full Text] [Related]
14. Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma.
Jiang T; Shi J; Dong Z; Hou L; Zhao C; Li X; Mao B; Zhu W; Guo X; Zhang H; He J; Chen X; Su C; Ren S; Wu C; Zhou C
J Hematol Oncol; 2019 Jul; 12(1):75. PubMed ID: 31299995
[TBL] [Abstract][Full Text] [Related]
15. Low PD-1 Expression in Cytotoxic CD8
Mazzaschi G; Madeddu D; Falco A; Bocchialini G; Goldoni M; Sogni F; Armani G; Lagrasta CA; Lorusso B; Mangiaracina C; Vilella R; Frati C; Alfieri R; Ampollini L; Veneziani M; Silini EM; Ardizzoni A; Urbanek K; Aversa F; Quaini F; Tiseo M
Clin Cancer Res; 2018 Jan; 24(2):407-419. PubMed ID: 29074606
[No Abstract] [Full Text] [Related]
16. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
17. HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.
Cheng H; Janakiram M; Borczuk A; Lin J; Qiu W; Liu H; Chinai JM; Halmos B; Perez-Soler R; Zang X
Clin Cancer Res; 2017 Feb; 23(3):825-832. PubMed ID: 27553831
[TBL] [Abstract][Full Text] [Related]
18. [Detection of ALK, ROS1 and RET fusion genes in non-small cell lung cancer patients and its clinicopathologic correlation].
Zhong S; Zhang H; Bai D; Gao D; Zheng J; Ding Y
Zhonghua Bing Li Xue Za Zhi; 2015 Sep; 44(9):639-43. PubMed ID: 26705279
[TBL] [Abstract][Full Text] [Related]
19. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis.
Meng X; Gao Y; Yang L; Jing H; Teng F; Huang Z; Xing L
Clin Lung Cancer; 2019 Jan; 20(1):48-58. PubMed ID: 30341017
[TBL] [Abstract][Full Text] [Related]
20. Tumor-infiltrating lymphocyte enrichment predicted by CT radiomics analysis is associated with clinical outcomes of non-small cell lung cancer patients receiving immune checkpoint inhibitors.
Park C; Jeong DY; Choi Y; Oh YJ; Kim J; Ryu J; Paeng K; Lee SH; Ock CY; Lee HY
Front Immunol; 2022; 13():1038089. PubMed ID: 36660547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
